Get startedLog in
    Picture of Basilea Pharmaceutica AG, Allschwil logo

    BSLN — Basilea Pharmaceutica AG, Allschwil News Story

    0.000.00%
    ch flag iconLast trade - 00:00
    HealthcareAdventurousMid CapHigh Flyer
    All News

    Brief: Basilea Receives $30 Million Funding For Advancing Phase 3 Development Of Novel Antifungal

    Picture of Basilea Pharmaceutica AG, Allschwil logoBasilea Pharmaceutica AG, Allschwil
    29/07/2026 06:18
    BRIEF-Basilea Receives $30 Million Funding For Advancing Phase 3 Development Of Novel Antifungal
    July 29 (Reuters) - BASILEA PHARMACEUTICA AG ALLSCHWIL BSLN.S:
    • RECEIVES USD 30 MILLION FUNDING UNDER EXISTING BARDA AGREEMENT FOR ADVANCING PHASE 3 DEVELOPMENT OF NOVEL ANTIFUNGAL FOSMANOGEPIX
    • BARDA POTENTIAL FUNDING TO BASILEA UP TO USD 268 MILLION OVER 12 YEARS
    Source text: ID:nGNE3ZH71J
    Further company coverage: BSLN.S

     (Gdansk Newsroom)
     ((gdansk.newsroom@thomsonreuters.com ; +48 587785269;;))

    Recent news on Basilea Pharmaceutica AG, Allschwil

    See all news